Hammond E H, Yowell R L, Price G D, Menlove R L, Olsen S L, O'Connell J B, Bristow M R, Doty D B, Millar R C, Karwande S V
Utah Transplantation Affiliated Hospitals Cardiac Transplant Program, LDS Hospital, University of Utah School of Medicine, Salt Lake City 84143.
J Heart Lung Transplant. 1992 May-Jun;11(3 Pt 2):S111-9.
We have prospectively monitored 268 patients by our previously described method of routine immunofluorescence of endomyocardial biopsy specimens. We have classified these patients according to their rejection pattern: cellular, vascular, and mixed. The criteria for these designations have been previously described. In this study we retrospectively reviewed coronary angiograms of these patients to assess the presence and time-course of developing allograft coronary artery disease. All available explanted hearts and postmortem hearts were also assessed by light microscopic examination for acute coronary vasculitis and allograft coronary artery disease and by immunofluorescent microscopy for vascular immune complex deposition in a manner identical to immunofluorescent microscopic examination of endomyocardial biopsy specimens. Patients were also monitored for sensitization to immunoprophylactically administered murine monoclonal CD3 antibody (OKT3) and those demonstrated to be sensitized were separately analyzed. Clinical features and treatment of patients were retrospectively reviewed. We found that 141 patients could be classified as having cellular rejection, 76 as having vascular rejection, and 52 as having a mixed rejection pattern. The allograft survival in vascular rejection patients was significantly worse than in allografts of patients with cellular or mixed rejection, confirming our earlier results. Most importantly, we found a significant difference in the time to the development of allograft coronary artery disease based on the rejection pattern. This difference existed whether or not patients sensitized to OKT3 were excluded from evaluation. Patients with mixed rejection had an intermediate time to the development of allograft coronary artery disease between that of patients with cellular and vascular rejection.(ABSTRACT TRUNCATED AT 250 WORDS)
我们采用先前描述的心肌内膜活检标本常规免疫荧光法,对268例患者进行了前瞻性监测。我们根据排斥反应模式对这些患者进行了分类:细胞性、血管性和混合性。这些分类标准先前已有描述。在本研究中,我们回顾性地查看了这些患者的冠状动脉造影,以评估同种异体移植冠状动脉疾病的存在情况和发展进程。所有可用的移植心脏和尸检心脏也通过光学显微镜检查急性冠状动脉血管炎和同种异体移植冠状动脉疾病,并通过免疫荧光显微镜检查血管免疫复合物沉积,检查方式与心肌内膜活检标本的免疫荧光显微镜检查相同。还对患者进行监测,以了解其对免疫预防性给予的鼠单克隆CD3抗体(OKT3)的致敏情况,并对那些被证明致敏的患者进行单独分析。对患者的临床特征和治疗进行了回顾性研究。我们发现,141例患者可归类为细胞性排斥,76例为血管性排斥,52例为混合性排斥模式。血管性排斥患者的同种异体移植存活率明显低于细胞性或混合性排斥患者的同种异体移植,这证实了我们先前的结果。最重要的是,我们发现基于排斥反应模式,同种异体移植冠状动脉疾病发展的时间存在显著差异。无论是否将对OKT3致敏的患者排除在评估之外,这种差异都存在。混合性排斥患者发生同种异体移植冠状动脉疾病的时间介于细胞性排斥和血管性排斥患者之间。(摘要截短于250字)